- Exelixis reported fourth-quarter earnings per share (EPS) of 48 cents, surpassing last year’s 27 cents and exceeding the estimated 45 cents.
- Total revenue for the quarter reached $566.8 million, marking an 18% increase year-over-year and surpassing the estimated $564.3 million.
- Net product revenues were reported at $515.2 million, a 20% rise from the previous year, exceeding the forecast of $508.3 million.
- License revenues increased by 9.1% year-over-year, totaling $49.3 million.
- Total operating expenses amounted to $403.5 million, showing a modest 1.4% increase and coming in lower than the estimated $412.5 million.
- Research and development (R&D) expenses were $249.0 million, a 1.8% increase from the prior year, yet below the expected $262 million.
- The company attributed its strong performance to the continued success of the cabozantinib franchise, generating substantial revenues both in the fourth quarter and the entire year of 2024.
- Regarding stock recommendations, 13 analysts have given a ‘buy’ rating, 9 have given a ‘hold’ recommendation, and 2 have advised ‘sell’.
“`
Exelixis Inc on Smartkarma
Analysts at Baptista Research have provided insightful coverage of Exelixis Inc on Smartkarma. In one report titled “Exelixis Inc.: These Are The 4 Biggest Challenges That Justify Our Lack Of Optimism! – Major Drivers,” the analysts highlighted the company’s robust financial position following the third-quarter results of 2024. They emphasized the strong performance of Exelixis’ flagship product, cabozantinib, and positive developments in its pipeline, particularly with zanzalintinib (zanza). Despite projecting substantial growth prospects and strategic collaborations, the analysts remain cautious, evaluating various factors that could impact the company’s stock price soon.
In another analysis titled “Exelixis Inc.: Expansion Of Cabometyx,” Baptista Research commended Exelixis, Inc. for its strong performance and strategic advancements in the second quarter of 2024. The company’s success in the cabozantinib franchise, especially in renal cell carcinoma (RCC), drove significant growth in both revenue streams and market presence. With net product revenues and partnership revenues totaling $618 million for the quarter, Exelixis Inc continues to demonstrate a solid financial standing and growth trajectory that analysts are closely monitoring on Smartkarma.
A look at Exelixis Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Exelixis Inc, a development-stage biotechnology company focusing on small-molecule therapeutics for cancer and other diseases, demonstrates a mixed outlook based on Smartkarma Smart Scores. With strong ratings in Growth and Momentum, the company is positioned well for future expansion and market dynamics. Its strategic alliances with major players in the pharmaceutical industry enhance its growth prospects.
However, lower scores in Dividend and average ratings in Value and Resilience may pose challenges for investors seeking stable income and value propositions. Despite this, Exelixis Inc‘s focus on developing innovative pharmaceutical products indicates its commitment to long-term sustainability and potential success in the competitive healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
